유럽 ​​헤파린 시장 – 2030년까지의 산업 동향 및 예측

유럽 ​​헤파린 시장 분석 및 규모

정맥혈전색전증과 심혈관질환의 증가는 시장 성장률에 영향을 미치는 주요 요인입니다. 나아가 정형외과 및 심장 수술을 포함한 다양한 수술에서 헤파린의 적용 횟수가 급증하고, 의료 인프라 개선을 위한 정부 지원이 증가하고, 노령 인구 증가로 인한 수술 수요 증가는 유럽 헤파린 시장을 확대할 요인입니다.

Data Bridge Market Research는 2022년에 3,472.05백만 달러였던 유럽 헤파린 시장이 2030년까지 6,586.83백만 달러에 도달할 것으로 예상되며, 2023-2030년 예측 기간 동안 5.83%의 CAGR을 보일 것으로 분석했습니다. "비분획 헤파린" 세그먼트는 헤파린 수요를 촉진하는 심혈관 질환의 유병률 증가로 인해 유럽 헤파린 시장의 제품 유형 세그먼트를 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

유럽 ​​헤파린 시장 범위 및 세분화

시장 정의

헤파린은 혈전을 예방하고 치료하는 약물입니다. 혈액 응고 이상을 치료하는 데 사용되는 약물입니다. 또한 수술 후, 수혈, 투석 및 혈액 샘플 채취 중에 혈액이 응고되는 것을 방지하는 데 사용됩니다. 항응고 단백질을 방출하여 혈액의 원활한 흐름을 돕습니다. 항응고제 라고 합니다 . 모두 DIC(Disseminated Intravascular Coagulation), 심부정맥혈전증, 폐색전증 및 동맥혈전색전증으로 치료합니다. 혈전을 제거하지는 않지만 혈전이 더 커지고 더 치명적인 합병증이 생기는 것을 방지합니다. 헤파린은 죽은 가축의 점막 조직에서 나오는 물질입니다.

유럽 ​​헤파린 시장 동향

운전자

• 심혈관 질환의 유병률 증가

The increasing incidence of cardiovascular diseases, such as deep vein thrombosis (DVT), pulmonary embolism, and coronary artery diseases, is a significant driver for the heparin market. Heparin is widely used for anticoagulation therapy in these conditions, driving demand.

• Growing Surgical Procedures

Surgical procedures, including open-heart surgeries, kidney dialysis, and organ transplants, often require anticoagulation therapy to prevent blood clots. Heparin's effectiveness in reducing clotting risk during surgeries fuels its demand.

• Advancements in Heparin Production

The development of low molecular weight heparin (LMWH) with improved safety and efficacy profiles has expanded heparin usage. LMWH is preferred in many clinical scenarios and is a driving factor in the market.

Opportunities

• Increasing Research and Development

Ongoing research into heparin derivatives and alternatives, as well as biosynthetic heparin production, presents opportunities for innovation in the market. These advancements may lead to safer and more effective anticoagulant therapies

• Growing Awareness of Thrombosis

Raising awareness about the risks of thrombosis and the benefits of anticoagulation therapy can drive market growth. Public health campaigns and educational initiatives can contribute to increased heparin use.

Restraints/ Challenges

• Regulatory Challenges

Stringent regulatory requirements for heparin production, especially in terms of quality and safety, can pose challenges for manufacturers. Compliance with these regulations is essential but can be costly and time-consuming.

• Competition from Novel Anticoagulants

Novel oral anticoagulants (NOACs), such as dabigatran and rivaroxaban, offer alternatives to traditional heparin therapy. These drugs are easier to administer and have a lower risk of HIT. Market competition from NOACs presents a challenge for heparin products.

This Europe heparin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe heparin market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2023, according to European Bioinformatics Institute Fibroblast growth factors are heparin-binding proteins, and interactions with cell surface-bound heparan sulphate proteoglycans have been found to be critical for FGF signaling

Europe Heparin Market Scope

Europe heparin market is segmented on the basis of product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Product Type

• Unfractionated Heparin
• Low Molecular Weight Heparin (LMWH)
• Ultra-Low Molecular Weight Heparin (ULMWH)

Mode of Administration

• Oral
• Parenteral

Source

• Bovine
• Porcine

Ingredients

• Sodium
• Calcium
• Others

Availability

• Raw
• Processed

 Treatment

• Deep Vein Thrombosis
• Pulmonary Embolism
• Arterial Thromboembolism
• Others

Application

• Pre-Surgical Procedures
• Post-Surgical Procedures
• Kidney Dialysis
• Diagnostic Tests
• Others

Therapeutics

• Cardiovascular
• Respiratory
• Oncology
• Nephrology
• CNS
• Others

Strength

• 10 unit
• 100 unit
• 1000 unit
• 5000 unit
• 10000 unit
• 25000 unit
• Others

Type

• Generics
• Brands

Container

• Bottles
• Bags
• Vials
• Others

Packaging

• Glass
• Plastic

 End User

• Hospital
• Clinics
• Homecare
• Ambulatory Surgical Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Drug Store
• Online Pharmacy
• Others

Europe Heparin Market Regional Analysis/Insights

Europe heparin market is analyzed and market size information is provided by the country, product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end user and distribution channel as referenced above.

The countries covered in this Europe heparin market report are Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, and Rest of Europe.

Germany dominates the Europe heparin market due to the presence of major key players, and developing healthcare infrastructure in this region. France and U.K. are expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, and growing prevalence of chronic disorders in this region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Heparin Market Share Analysis

유럽 ​​헤파린 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 유럽 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 유럽 헤파린 시장 조사와 관련된 회사의 초점에만 관련이 있습니다.

유럽 ​​헤파린 시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• Aspen Holdings(남아프리카 공화국)
• Changzhaou Qianhong Bio-pharma Co., Ltd. (중국)
• 에자이 주식회사(일본)
• Fresenius Kabi AG(독일)
• 허베이 창산 바이오케미컬 파마슈티컬 유한회사(중국)
• 히크마 파마슈티컬스 PLC(요르단)
• LEO Pharma A/S(덴마크)
• 노바티스 AG(스위스)
• SARIA A/S GmbH & Co. KG(독일)
• 오포크린 스파(이탈리아)
• 브리스톨-마이어스 스퀴브 회사(미국)
• GlaxoSmithKline plc. (영국)
• Dr. Reddy's Laboratories Ltd. (인도)
• B. Braun Melsungen AG(독일)
• Baxter(미국)

SKU-43607